Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
On Wednesday, Merck & Co Inc (NYSE:MRK) reported second-quarter sales of $16.1 billion, up 7% year-over-year, beating the consensus estimate of $15.84 billion. Excluding the impact of foreign exchange, sales increased 11%.
週三，默沙東公司（紐約證券交易所代碼：MRK）公佈第二季度銷售額爲161億美元，同比增長7％，超過市場普遍預期的158.4億美元。不包括外匯的影響，銷售額增長了11％。
Merck reported adjusted EPS of $2.28, a shift from an EPS loss of $(2.06), beating the consensus of $2.15.
默沙東報告調整後的每股收益爲2.28美元，較每股收益虧損2.06美元（2.06美元）有所變化，超過了市場普遍的2.15美元。
The pharmaceutical unit booked $14.41 billion in revenue, up 7% year over year. Growth in oncology, cardiovascular, and vaccines, partially offset by declines in diabetes and virology, drove the growth.
該製藥部門的收入爲144.1億美元，同比增長7％。腫瘤學、心血管和疫苗的增長部分被糖尿病和病毒學的下降所抵消，推動了增長。
Also Read: Merck Gets Legal Victory As Appeals Court Dismisses Shingles Vaccine Some 1,200 Lawsuits.
另請閱讀：上訴法院駁回了約1,200起帶狀皰疹疫苗訴訟，默沙東獲得了法律勝利。
Merck's blockbuster cancer immunotherapy Keytruda generated $7.27 billion in revenue during the quarter, up 16% from the year-earlier period.
默克重磅癌症免疫療法Keytruda在本季度創造了72.7億美元的收入，比去年同期增長了16％。
Merck also reported a marginal increase of 1% in sales of Gardasil to $2.48 billion, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S. Growth was largely offset by lower sales in China.
默沙東還報告稱，Gardasil的銷售額小幅增長了1％，達到24.8億美元。HPV是一種預防HPV（美國最常見的性傳播感染）致癌的疫苗。增長在很大程度上被中國銷售的下降所抵消。
The newly approved Winrevair (sotatercept) for adults with pulmonary arterial hypertension generated sales of $70 million.
新批准的用於成人肺動脈高壓的Winrevair（sotatercept）的銷售額爲7,000萬美元。
During the quarter, the FDA approved Merck's Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 21 strains of bacteria to prevent a severe form of pneumococcal disease, as the first pneumococcal conjugate vaccine specifically designed to protect adults.
在本季度，美國食品和藥物管理局批准了默克公司的Capvaxive（肺炎球菌21價偶聯疫苗），以預防21種細菌菌株，以預防嚴重的肺炎球菌疾病，這是第一種專門爲保護成年人而設計的肺炎球菌偶聯疫苗。
Also, the company, with its partner Daiichi Sankyo (OTC:DSKYF) (OTC:DSNKY) received an FDA Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking accelerated approval of patritumab deruxtecan (HER3-DXd) for a certain type lung cancer.
此外，該公司與其合作伙伴第一三共公司（場外交易代碼：DSNKY）（場外交易代碼：DSNKY）收到了美國食品藥品管理局生物製劑許可申請（BLA）的完整回覆信（CRL），要求加快批准用於特定類型肺癌的帕曲單抗德魯斯特康（HER3-DxD）。
Guidance: Merck revised and narrowed its full-year 2024 forecasts.
指導：默沙東修訂並縮小了其2024年全年預測。
The company expects 2024 sales of $63.4 billion—$64.4 billion, compared to previous guidance of $63.1 billion—$64.3 billion and the consensus of $64.34 billion.
該公司預計，2024年的銷售額爲634億美元至644億美元，而之前的預期爲631億美元至643億美元，共識爲643.4億美元。
The U.S. pharma giant expects 2024 adjusted EPS of $7.94 to $8.04, compared to prior guidance of $8.53-$8.65 and consensus of $8.16.
這家美國製藥巨頭預計，2024年調整後的每股收益爲7.94美元至8.04美元，而之前的預期爲8.53-8.65美元，共識爲8.16美元。
The outlook includes one-time charges of $0.77 per share For Harpoon and Eyebio acquisitions.
展望包括收購Harpoon和Eyebio的每股0.77美元的一次性費用。
Price Action: MRK stock is down 3.19% at $123.70 during the premarket session at last check Tuesday.
價格走勢：在週二最後一次盤前交易中，MrK股價下跌3.19％，至123.70美元。
- Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants.
- 默沙東與賽諾菲/阿斯利康競爭，因爲其呼吸道合胞病毒治療藥物在嬰兒後期研究中達到了主要目標。
Photo Courtesy of Merck
照片由默沙東提供